Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

PURPOSE: In patients with diffuse large B-cell lymphoma (DLBCL), most relapses occur within the first 2 years of diagnosis. We sought to define the rate and outcome of late relapses that occurred after achieving event-free survival at 24 months (EFS24). METHODS: We prospectively followed 1,324 patie...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Wang, Yucai, Farooq, Umar, Link, Brian K., Larson, Melissa C., King, Rebecca L., Maurer, Matthew J., Allmer, Cristine, Hefazi, Mehrdad, Thompson, Carrie A., Micallef, Ivana N., Johnston, Patrick B., Habermann, Thomas M., Witzig, Thomas E., Ansell, Stephen M., Cerhan, James R., Nowakowski, Grzegorz S.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2019
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7001527/
https://ncbi.nlm.nih.gov/pubmed/31170029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00014
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk